Swapnil Malekar's questions to Immuneering (IMRX) leadership • Q4 2022
Question
Swapnil Malekar from Piper Sandler inquired about the number of patients dosed in the IMM-1-104 trial and the specifics of new data being presented at the upcoming AACR conference, particularly regarding tumor type or mutation status trends.
Answer
President and CEO Benjamin Zeskind deferred on providing specific patient numbers, referencing the detailed guidance on data readouts already shared. Regarding the AACR poster, Zeskind and Chief Scientific Officer Brett Hall emphasized its demonstration of "universal-RAS" activity, noting that approximately 85% of the 75 RAS-mutant models tested showed a response, with no single mutation appearing resistant. Hall described the poster as a comprehensive look at their proprietary 3D tumor growth assay platform.